AlivaMab Discovery Services Announces Planned Leadership Transition

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

AlivaMab Discovery Services, LLC, (“ADS”) a leader in comprehensive, integrated solutions for antibody drug discovery, announced the planned transition of its chief executive officer from Larry Green, PhD, to Justin Mika, effective May 6, 2020. Dr. Green will become chairman of the board of directors of ADS. Dr. Green remains as CEO of Ablexis, LLC and will continue to work closely with the team at ADS to advance the companies’ combined goal of delivering antibody drug candidates of the highest quality.

As CEO, Mr. Mika will lead the continued growth of ADS’ business as the best-in-class provider of antibody drug discovery platform services. He joins ADS from Eurofins DiscoverX, where he was senior vice president of the drug discovery division at Eurofins and General Manager of Eurofins DiscoverX. Joining DiscoverX in 2006, he helped grow the company through roles of increasing responsibility, finally serving as Senior Vice President and General Manager in its acquisition by Eurofins in 2017. He has a B.Sc., Biology and Molecular Biology Concentration from Pennsylvania State University and a M.Sc. in Organizational Development and Change Management and a Masters of Business Administration degree from the University of Delaware.

Justin’s track record of success evidences that he is the perfect fit to lead AlivaMab Discovery Services in its next phases of growth, said Dr. Green. He understands our market, is an experienced leader and possesses a customer-first mindset. Under his leadership, ADS will advance performance and operational improvements and innovations to deliver even better client satisfaction.

I am extremely proud of the accomplishments of the ADS team in building the business and repeatedly demonstrating the ability to produce and identify, in only a few weeks, diverse panels of candidate-quality human antibodies for both straightforward and challenging projects for our clients, Dr. Green continued. I am also proud that in only one year of client services, ADS is exceeding its business metrics, including repeat customers, new customers and revenue growth. Personally, this is a bittersweet decision for me, saddening to leave the day-to-day workings with the ADS family and happy to return to San Francisco for more time with my partner and dogs.

I look forward to working with the talented team at ADS and am pleased that the board of directors has entrusted me to lead its ongoing innovation and expansion, said Mr. Mika. The integrated, comprehensive offerings of ADS combined with Ablexis’ AlivaMab Mouse platform hit the sweet spot between competitors’ offerings. The clients of ADS, which range from global pharmaceutical companies to companies operating virtually, understand that the success of a project, both in the short-term and long-term, is founded on what ADS does best: efficiently and cost-effectively generating, characterizing and delivering fully human antibodies that meet target product profiles in industry-leading timelines.

About AlivaMab Discovery Services (ADS)

AlivaMab Discovery Services is dedicated to our partners’ successes in the discovery and development of human therapeutic antibodies. ADS fully-integrated therapeutic antibody discovery platform leverages the teams expertise built on cumulative decades of experience in building and using antibody drug discovery platforms and processes, which includes the execution of over 200 discovery projects that has yielded several dozen antibody drug candidates in clinical trials, and seven approved antibody drugs. Our drug discovery experience crosses diverse therapeutic areas including oncology, autoimmune and inflammatory disease, metabolic, ocular, and infectious disease.

AlivaMab Discovery Services uses the AlivaMab Mouse of Ablexis, LLC to deliver panels of high affinity therapeutic antibody candidates, with extensive molecular and epitope diversities, functional and kinetic characterization, with unmatched speed. With the broad and deep expertise of the ADS team, we develop innovative solutions for immunizations, antibody recovery, antibody screening, and functional assay development and execution for even the most difficult project to give clients of ADS a distinct advantage for their antibody drug discovery projects.

For more information, please visit or contact us at [email protected].

Christine Quern

[email protected]